Pharmaceuticals, Biotechnology and Life Sciences
The Wasdell Group (Wasdell), a leading outsourcing partner for companies in the pharmaceutical and clinical trials industries, has been granted its Health Products Regulatory Authority (HPRA) licence for its new EU headquarters in Dundalk, Ireland.
In line with KRAIBURG TPE’s 2019 strategy to increase its focus on medical applications and pharmaceutical packaging, the company recently collaborated with Eastman to develop a range of innovative high-purity TPEs. In close cooperation with Eastman, KRAIBURG TPE has developed a range of THERMOLAST® M thermoplastic elastomers (TPEs) with the capability to adhere directly to specialized polymers used in medical applications, including Eastman’s Tritan™ copolyester, PP, ABS, ABS/PC, and PET.
Trovagene has expanded the use of Onvansertib to enable it for combination therapies with anti-androgen drugs, like Zytiga, Xtandi and Erledea to treat castrate-resistant prostate cancer.
Actinium Pharmaceuticals has appointed Cynthia Pussinen as Executive Vice President, Technical Operations and Supply Chain, who will also serve as a member of Actinium’s executive leadership team.
Biohaven Pharmaceutical started a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheimer’s disease (AD).
Second Genome has dosed first patient in a Phase 2 test of its oral, small molecule inhibitor of P2X7, called SGM-1019, for treating nonalcoholic steatohepatitis (NASH).
Alvotech has raised $300 million through a private bond offering to fuel continued growth, refinance of existing debt and the further development of Alvotech’s biosimilar assets.
Wren Therapeutics has cashed in £18 million from an international syndicate led by The Baupost Group, in a Series A financing round, which also included LifeForce Capital and a number of high net worth individual investors, the company said Tuesday.
TWi Biotechnology has enrolled patients in its Phase 2 clinical trial of AC-203 for the treatment of inherited Epidermolysis Bullosa (EB).
Oramed Pharmaceuticals has started recruiting patients for its first study of
oral GLP-1 capsule ORMD-0901 under Oramed’s existing FDA Investigational New Drug application (IND), in Phase 1 (PK) pharmacokinetic study.